JUST IN: ‘Availability Of Lenacapavir Treatment  In 2025 Set To Transform Global Health,’ Says CDC Kenya’s Director 

  KISII, Kenya, Oct 23 – The U.S Food and Drug Administration ( FDA) has confirmed the availability of  lenacapavir, a two yearly injectable HIV/ADS treatment as early as summer 2025, a decision made by FDA after the completion of phase 3 trial of lenacapavir treatment. In an interview with Capital FM  Centers for Disease Control Read More